Literature DB >> 17704407

Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: the hidden face of estrogens.

Olivier Cussenot1, Abdel Rhamene Azzouzi, Nathalie Nicolaiew, Gaelle Fromont, Philippe Mangin, Luc Cormier, Georges Fournier, Antoine Valeri, Stephane Larre, Frederic Thibault, Jean-Pierre Giordanella, Michel Pouchard, Yan Zheng, Freddie C Hamdy, Angela Cox, Geraldine Cancel-Tassin.   

Abstract

PURPOSE: The association between common functional polymorphisms from the CYP17, CYP19, CYP1B1, and COMT genes involved in the estrogen metabolism and the risk of prostate carcinoma was evaluated. PATIENTS AND METHODS: The study investigated 1,983 white French men (1,101 patients with prostate cancer and 882 healthy controls) aged between 40 and 98 years. The different alleles and genotypes were analyzed according to case-control status, aggressiveness pattern of the tumors, age at onset, and family history of cancers.
RESULTS: The VV (high activity) genotype of the V432L polymorphism from CYP1B1 (odds ratio [OR] = 1.36; 95% CI, 1.03 to 1.79; P = .031), and the long allele (> 175 bp) of the TTTA repeat from CYP19 (OR, 1.26; 95% CI, 1.08 to 1.47; P = .003) were significantly associated with the risk of prostate cancer. An additive effect was observed when we combined the two at-risk alleles (OR = 1.63; 95% CI, 1.24 to 2.13; P < .001). The association was stronger for the CYP1B1 VV genotype (OR = 1.55; 95% CI, 1.13 to 2.13; P = .007) among the group of patients with highly aggressive disease. Stratification by age at onset showed that the associations of CYP1B1 and CYP19 variants were largely confined to the younger prostate cancer patients.
CONCLUSION: This association between polymorphisms from genes related to estrogen metabolism and prostate cancer risk suggest new clinical considerations in the management of prostate cancer: the development of new prevention trials based on genetic profiling and the evaluation of specific inhibitors involving the estrogen pathways.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17704407     DOI: 10.1200/JCO.2007.11.0908

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  31 in total

1.  Unbalanced estrogen metabolism in ovarian cancer.

Authors:  Muhammad Zahid; Cheryl L Beseler; James B Hall; Tricia LeVan; Ercole L Cavalieri; Eleanor G Rogan
Journal:  Int J Cancer       Date:  2014-01-25       Impact factor: 7.396

2.  Correlation between prostate volume and single nucleotide polymorphisms implicated in the steroid pathway.

Authors:  Jean-Nicolas Cornu; Etienne Audet-Walsh; Sarah Drouin; Pierre Bigot; Antoine Valeri; Georges Fournier; Abdel-Rahmène Azzouzi; Morgan Roupret; Luc Cormier; Stephen Chanock; Chantal Guillemette; Olivier Cussenot; Eric Lévesque; Géraldine Cancel-Tassin
Journal:  World J Urol       Date:  2016-06-08       Impact factor: 4.226

3.  The CYP1B1 Leu432Val polymorphism and risk of urinary system cancers.

Authors:  Yi Liu; Chang-sheng Lin; Ai-min Zhang; Hua Song; Chang-chun Fan
Journal:  Tumour Biol       Date:  2014-01-23

Review 4.  Prostate cancer: from the pathophysiologic implications of some genetic risk factors to translation in personalized cancer treatments.

Authors:  C R Balistreri; G Candore; D Lio; G Carruba
Journal:  Cancer Gene Ther       Date:  2014-01-10       Impact factor: 5.987

5.  Association between the CYP1B1 polymorphisms and risk of cancer: a meta-analysis.

Authors:  Jie-Ying Liu; Yu Yang; Zhi-Zhong Liu; Jian-Jun Xie; Ya-Ping Du; Wei Wang
Journal:  Mol Genet Genomics       Date:  2014-12-05       Impact factor: 3.291

6.  Tobacco and estrogen metabolic polymorphisms and risk of non-small cell lung cancer in women.

Authors:  Michele L Cote; Wonsuk Yoo; Angela S Wenzlaff; Geoffrey M Prysak; Susan K Santer; Gina B Claeys; Alison L Van Dyke; Susan J Land; Ann G Schwartz
Journal:  Carcinogenesis       Date:  2009-01-27       Impact factor: 4.944

7.  The l58Val/Met polymorphism of catechol-O-methyl transferase gene and prostate cancer risk: a meta-analysis.

Authors:  Li Xiao; Ming Tong; Yanyang Jin; Weichao Huang; Zizhi Li
Journal:  Mol Biol Rep       Date:  2012-10-21       Impact factor: 2.316

8.  An aromatase polymorphism modulates the relationship between weight and estradiol levels in obese men.

Authors:  Ahmad Hammoud; Douglas T Carrell; A Wayne Meikle; Yuanpei Xin; Steven C Hunt; Ted D Adams; Mark Gibson
Journal:  Fertil Steril       Date:  2009-12-11       Impact factor: 7.329

9.  Quantified gene expression levels for phase I/II metabolizing enzyme and estrogen receptor levels in benign prostate from cohorts designated as high-risk (UK) versus low-risk (India) for adenocarcinoma at this organ site: a preliminary study.

Authors:  Paras B Singh; Narasimhan Ragavan; Katherine M Ashton; Prabir Basu; Sayeed M Nadeem; Caroline M Nicholson; R K Gopala Krishna; Shyam S Matanhelia; Francis L Martin
Journal:  Asian J Androl       Date:  2009-11-23       Impact factor: 3.285

10.  CYP19A1 genetic variation in relation to prostate cancer risk and circulating sex hormone concentrations in men from the Breast and Prostate Cancer Cohort Consortium.

Authors:  Ruth C Travis; Fredrick Schumacher; Joel N Hirschhorn; Peter Kraft; Naomi E Allen; Demetrius Albanes; Goran Berglund; Sonja I Berndt; Heiner Boeing; H Bas Bueno-de-Mesquita; Eugenia E Calle; Stephen Chanock; Alison M Dunning; Richard Hayes; Heather Spencer Feigelson; J Michael Gaziano; Edward Giovannucci; Christopher A Haiman; Brian E Henderson; Rudolf Kaaks; Laurence N Kolonel; Jing Ma; Laudina Rodriguez; Elio Riboli; Meir Stampfer; Daniel O Stram; Michael J Thun; Anne Tjønneland; Dimitrios Trichopoulos; Paolo Vineis; Jarmo Virtamo; Loïc Le Marchand; David J Hunter
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-09-29       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.